SB 142 updates regulations for group health insurance plans used by Alaska municipalities and the state government, including how pharmacy benefits are managed. It requires municipal plans (including self-insured ones) and their pharmacy benefits managers to follow specific state laws (AS 21.27.901-21.27.975 and AS 21.36.520), unless covered by federal ERISA. For the state, it clarifies procurement rules, mandating that the Department of Administration must follow dual choice requirements, obtain bids from authorized insurers, and select the lowest responsible bid for group health insurance. This bill directly affects municipal and state employee health coverage, pharmacy benefit administration, and the process for selecting insurance providers.
HB 225 allows pharmacists to dispense fluoride supplements without an individual prescription, provided they operate under a standing order approved under existing law (AS 17.20.087). This directly affects pharmacists and patients seeking fluoride supplements for dental health. The bill requires pharmacists to provide patient counseling on proper administration, storage, side effects, and risks of the supplements. It amends pharmacy practice regulations to clarify this dispensing authority while maintaining safety requirements. The bill does not address fluoride in public water systems, as referenced in the title but not detailed in the provided text.
HB 195 expands pharmacists' authority to independently prescribe and administer certain medications. It allows pharmacists to prescribe vaccines and opioid overdose drugs (like naloxone) without a physician's order, provided they complete board-approved training programs. The bill also updates licensing standards, requires pharmacists to register controlled substance prescriptions in a state database, and clarifies pharmacy facility and equipment requirements. These changes directly affect licensed pharmacists in Alaska and patients seeking vaccinations or emergency overdose treatment. The bill amends existing pharmacy practice laws to modernize pharmacist roles while maintaining safety oversight.
SB 134 amends Alaska's insurance code to expand regulatory oversight of pharmacy benefits managers (PBMs) and third-party administrators. The bill requires the state insurance director to examine these entities whenever necessary, adding them to the list of entities subject to routine financial and operational reviews. It also clarifies that these entities must be licensed to operate in Alaska and establishes payment procedures for examination costs. The bill directly affects PBMs and third-party administrators providing pharmacy benefit services in the state, increasing their regulatory compliance obligations.
HB 149 expands regulatory oversight of pharmacy benefits managers (PBMs) and third-party administrators in Alaska. It amends insurance code to explicitly include PBMs and third-party administrators in the director’s authority to conduct examinations, requiring them to be inspected under the same standards as other insurance entities. The bill also clarifies examination fees and licensing requirements for these entities, ensuring they must be licensed to operate in Alaska and pay reasonable costs for regulatory reviews. This focuses on strengthening accountability for entities managing pharmacy benefits, directly affecting PBMs and third-party administrators operating in the state.
SB 147 expands pharmacists' authority in Alaska to independently prescribe and administer certain medications, including vaccines and opioid overdose drugs, without a doctor's direct order. It requires pharmacists to complete specific training programs (e.g., for epinephrine use or opioid overdose response) and register controlled substance prescriptions in a state database. The bill also updates licensing standards, including language fluency and program approval requirements for pharmacy schools, and clarifies the Board of Pharmacy's regulatory powers. These changes directly affect pharmacists (by broadening their clinical roles), patients (by increasing access to care), and the pharmacy board (by strengthening oversight).
